Table 3.
1 | Perindopril plus amlodipine | Claim | Perindopril/amlodipine with stronger and superior BP reduction as compared to telmisartan/amlodipine and olmesartan/amlodipine |
Analysis | The referenced study dealt with the efficacy of perindopril/amlodipine as antihypertensive agents only, with no comparison to other drug combinations [24, 25] | ||
| |||
2 | Moxifloxacin | Claim | Used in Multidrug Resistant TB |
Analysis | Approved by FDA for nontubercular infections but it is under phase 3 trials for use in tuberculosis [26] | ||
| |||
3 | Vitamin D3 | Claim | Increases Bone Mineral Density (BMD) by 25% within 2 years |
Analysis | Referenced study affirmed increase in BMD on vitamin D3 therapy but not by 25% in 2 years [27] | ||
| |||
4 | Duloxetine | Claim | Offers advantage in terms of efficacy over SSRIs |
Analysis | (i) No significant advantage has been seen in comparison to SSRIs [28, 29] (ii) SSRIs are the most commonly prescribed 1st line agents in treatment of anxiety and major depressive disorder due to their better safety and efficacy profile [28, 29] (iii) No reference was quoted in support |